bioAffinity Technologies Files 8-K
Ticker: BIAFW · Form: 8-K · Filed: Oct 7, 2025 · CIK: 1712762
Sentiment: neutral
Topics: 8-K, filing, SEC
Related Tickers: BIAF
TL;DR
BIAF filed a routine 8-K on Oct 7, 2025. No major news.
AI Summary
On October 7, 2025, bioAffinity Technologies, Inc. filed an 8-K report. The filing indicates no specific material events or financial updates were disclosed on this date, but it serves as a routine filing for the company.
Why It Matters
This filing is a standard disclosure for publicly traded companies, indicating that bioAffinity Technologies, Inc. has submitted a current report to the SEC.
Risk Assessment
Risk Level: low — This filing is a standard current report with no disclosed material events, thus posing a low immediate risk.
Key Players & Entities
- bioAffinity Technologies, Inc. (company) — Registrant
- October 7, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- San Antonio, Texas (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for bioAffinity Technologies, Inc.?
The filing is a Current Report on Form 8-K, indicating that bioAffinity Technologies, Inc. is reporting information under Section 13 or 15(d) of the Securities Exchange Act of 1934.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on October 7, 2025.
In which state is bioAffinity Technologies, Inc. incorporated?
bioAffinity Technologies, Inc. is incorporated in Delaware.
What is the principal executive office address for bioAffinity Technologies, Inc.?
The principal executive office address is 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217.
Does this 8-K filing disclose any specific material events or financial updates?
Based on the provided text, this 8-K filing is a routine current report and does not explicitly detail any specific material events or financial updates.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-10-07 17:16:41
Key Financial Figures
- $0.007 — ch registered Common Stock, par value $0.007 per share BIAF The Nasdaq Stock Mar
Filing Documents
- form8-k.htm (8-K) — 48KB
- ex99-1.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 18KB
- ex99-1_002.jpg (GRAPHIC) — 8KB
- 0001493152-25-017328.txt ( ) — 312KB
- biaf-20251007.xsd (EX-101.SCH) — 4KB
- biaf-20251007_def.xml (EX-101.DEF) — 26KB
- biaf-20251007_lab.xml (EX-101.LAB) — 36KB
- biaf-20251007_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 7, 2025 BIOAFFINITY TECHNOLOGIES, INC. By: /s/ Maria Zannes Name: Maria Zannes Title: President and Chief Executive Officer -3-